Maraviroc
SELZENTRY
CCR5 Co-receptor Antagonist
NADAC/unit
$8.9631
No Shortage
Tier 1: 55.9%
4 Manufacturers
8 ANDAs
vs. brand SELZENTRY: Generic saves up to 10% per unit
Active Shortages
2026-01-20 The anticipated date that GSK will cease distribution of the product is approximately August 1, 2026., ViiV Healthcare Company
Generic Manufacturers
HETERO LABS LTD UNIT IIII 3 PHARMACEUTICALS LLCNAVINTA LLCRHODES PHARMACEUTICALS LPVIIV HEALTHCARE CO
Explore in the Ecosystem
Data sourced from CMS NADAC, FDA Orange Book, CMS Part D Formulary, CMS Part D Spending, openFDA, and HRSA 340B OPAIS. Prices reflect National Average Drug Acquisition Cost and may not represent actual transaction prices. This information is for research and comparison purposes only. Consult your pharmacist or benefits consultant for plan-specific pricing.